{"transactions":[{"id":4622872,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-18T20:15:03.000Z","date":"2026-09-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":473,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 38,402 shares of Common Stock and 3,433 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":41853,"source":{"system":"sec-edgar","filing":"0001193125-26-395552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526395552/ownership.xml","form_type":"4"}},{"id":725967,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-26T21:20:02.000Z","date":"2026-06-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":988,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 37,158 shares of Common Stock and 5,150 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":42308,"source":{"system":"sec-edgar","filing":"0001193125-26-285722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526285722/ownership.xml","form_type":"4"}},{"id":828705,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-25T20:35:02.000Z","date":"2026-03-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":988,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 34,553 shares of Common Stock and 8,743 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":43296,"source":{"system":"sec-edgar","filing":"0001193125-26-124231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526124231/ownership.xml","form_type":"4"}},{"id":918398,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67624,"kind":"person","name":"Sullivan Eddie Joe","position":1,"cik":"0001889712","reported_name":"Sullivan Eddie Joe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Stock option (right to buy)","published_at":"2026-02-05T21:55:03.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":3000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":3000000,"derivative":{"exercise_price":4.45,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":3000000},"source":{"system":"sec-edgar","filing":"0001193125-26-039577","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526039577/ownership.xml","form_type":"4"}},{"id":918397,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67623,"kind":"person","name":"Reich Samuel J","position":1,"cik":"0001394645","reported_name":"Reich Samuel J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-02-05T21:50:05.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":4800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":4800000,"derivative":{"exercise_price":4.45,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":4800000},"source":{"system":"sec-edgar","filing":"0001193125-26-039564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526039564/ownership.xml","form_type":"4"}},{"id":918396,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock option (right to buy)","published_at":"2026-02-05T21:45:03.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":1800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":1800000,"derivative":{"exercise_price":4.45,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":1800000},"source":{"system":"sec-edgar","filing":"0001193125-26-039537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526039537/ownership.xml","form_type":"4"}},{"id":918395,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock option (right to buy)","published_at":"2026-02-05T21:40:02.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":2400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":2400000,"derivative":{"exercise_price":4.45,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":2400000},"source":{"system":"sec-edgar","filing":"0001193125-26-039524","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526039524/ownership.xml","form_type":"4"}},{"id":918394,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67621,"kind":"person","name":"To Lucy","position":1,"cik":"0002032049","reported_name":"To Lucy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock option (right to buy)","published_at":"2026-02-05T21:35:02.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":2400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":2400000,"derivative":{"exercise_price":4.45,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":2400000},"source":{"system":"sec-edgar","filing":"0001193125-26-039508","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526039508/ownership.xml","form_type":"4"}},{"id":945263,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":32667,"kind":"person","name":"Jain Rita","position":1,"cik":"0001707797","reported_name":"Jain Rita","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T21:41:02.000Z","date":"2026-01-05","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029."}],"balance_after":240000,"derivative":{"exercise_price":3.74,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001193125-26-006435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526006435/ownership.xml","form_type":"4"}},{"id":945262,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":31235,"kind":"person","name":"ZACCARDELLI DAVID","position":1,"cik":"0001627642","reported_name":"ZACCARDELLI DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T21:40:03.000Z","date":"2026-01-05","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029."}],"balance_after":240000,"derivative":{"exercise_price":3.74,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001193125-26-006427","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526006427/ownership.xml","form_type":"4"}},{"id":963752,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67940,"kind":"person","name":"SKYLER JAY S","position":1,"cik":"0001236386","reported_name":"SKYLER JAY S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-18T21:55:03.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."}],"balance_after":150000,"derivative":{"exercise_price":3.99,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-325007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525325007/ownership.xml","form_type":"4"}},{"id":963751,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71237,"kind":"person","name":"Polvino William James","position":1,"cik":"0001889459","reported_name":"Polvino William James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-18T21:53:03.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."}],"balance_after":150000,"derivative":{"exercise_price":3.99,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-325002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525325002/ownership.xml","form_type":"4"}},{"id":963750,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":22905,"kind":"person","name":"Lucera Erick","position":1,"cik":"0001697616","reported_name":"Lucera Erick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-12-18T21:50:03.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."}],"balance_after":150000,"derivative":{"exercise_price":3.99,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-324991","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525324991/ownership.xml","form_type":"4"}},{"id":963749,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71236,"kind":"person","name":"Ellias Helen K.","position":1,"cik":"0002001600","reported_name":"Ellias Helen K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-18T21:45:03.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."}],"balance_after":150000,"derivative":{"exercise_price":3.99,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-324976","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525324976/ownership.xml","form_type":"4"}},{"id":963748,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71235,"kind":"person","name":"Giberson Scott","position":1,"cik":"0001937585","reported_name":"Giberson Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-18T21:43:03.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."}],"balance_after":150000,"derivative":{"exercise_price":3.99,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-324970","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525324970/ownership.xml","form_type":"4"}},{"id":963747,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71234,"kind":"person","name":"Link David","position":1,"cik":"0002085171","reported_name":"Link David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-18T21:40:03.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027."}],"balance_after":150000,"derivative":{"exercise_price":3.99,"expiration_date":"2035-12-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-324963","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525324963/ownership.xml","form_type":"4"}},{"id":972014,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-12-12T21:45:02.000Z","date":"2025-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":988,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 31,946 shares of Common Stock and 12,338 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":44284,"source":{"system":"sec-edgar","filing":"0001193125-25-317688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525317688/ownership.xml","form_type":"4"}},{"id":1030009,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-10-01T20:35:03.000Z","date":"2025-09-29","kind":"exercise","planned":false,"acquired":false,"shares":17400,"ownership":{"direct":false,"nature":"See Footnote."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (the \"Common Stock\") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Sessa Parties from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Sessa Parties beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Sessa Parties from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Sessa Parties beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Sessa Parties from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Sessa Parties beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the \"Sessa Parties\"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":211100,"derivative":{"exercise_price":1.75,"exercise_date":"2025-09-29","underlying":"Common Stock","underlying_shares":1740000},"source":{"system":"sec-edgar","filing":"0001193125-25-226846","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525226846/ownership.xml","form_type":"4"}},{"id":1030008,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-01T20:35:03.000Z","date":"2025-09-29","kind":"exercise","planned":false,"acquired":true,"shares":1740000,"price":1.75,"value":3045000.0,"ownership":{"direct":false,"nature":"See Footnote."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (the \"Common Stock\") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the \"Sessa Parties\"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":2198457,"source":{"system":"sec-edgar","filing":"0001193125-25-226846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525226846/ownership.xml","form_type":"4"}},{"id":1030007,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-10-01T20:06:19.000Z","date":"2025-09-29","kind":"exercise","planned":false,"acquired":false,"shares":17400,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (the \"Common Stock\") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Reporting Persons from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Reporting Persons from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Reporting Persons from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":211100,"derivative":{"exercise_price":1.75,"exercise_date":"2025-09-29","underlying":"Common Stock","underlying_shares":1740000},"source":{"system":"sec-edgar","filing":"0001012975-25-000592","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000101297525000592/form4.xml","form_type":"4"}},{"id":1030006,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-01T20:06:19.000Z","date":"2025-09-29","kind":"exercise","planned":false,"acquired":true,"shares":1740000,"price":1.75,"value":3045000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (the \"Common Stock\") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":2198457,"source":{"system":"sec-edgar","filing":"0001012975-25-000592","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000101297525000592/form4.xml","form_type":"4"}},{"id":1035212,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-22T21:00:04.000Z","date":"2025-09-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":1977,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 29,340 shares of Common Stock and 15,932 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":45272,"source":{"system":"sec-edgar","filing":"0001193125-25-211490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525211490/ownership.xml","form_type":"4"}},{"id":1054162,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67623,"kind":"person","name":"Reich Samuel J","position":1,"cik":"0001394645","reported_name":"Reich Samuel J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & EXECUTIVE CHAIRMAN"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-28T21:15:05.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":4800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share (\"Common Stock\"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the \"Plan\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":4800000,"derivative":{"exercise_price":2.17,"expiration_date":"2035-08-26","underlying":"Common Stock","underlying_shares":4800000},"source":{"system":"sec-edgar","filing":"0000950170-25-112077","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025112077/ownership.xml","form_type":"4"}},{"id":1054161,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67621,"kind":"person","name":"To Lucy","position":1,"cik":"0002032049","reported_name":"To Lucy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-28T21:10:04.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share (\"Common Stock\"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the \"Plan\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":1200000,"derivative":{"exercise_price":2.17,"expiration_date":"2035-08-26","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0000950170-25-112056","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025112056/ownership.xml","form_type":"4"}},{"id":1054160,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-28T21:00:12.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":2400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share (\"Common Stock\"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the \"Plan\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":2400000,"derivative":{"exercise_price":2.17,"expiration_date":"2035-08-26","underlying":"Common Stock","underlying_shares":2400000},"source":{"system":"sec-edgar","filing":"0000950170-25-112047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025112047/ownership.xml","form_type":"4"}},{"id":1054159,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-28T21:00:09.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share (\"Common Stock\"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the \"Plan\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":600000,"derivative":{"exercise_price":2.17,"expiration_date":"2035-08-26","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000950170-25-112045","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025112045/ownership.xml","form_type":"4"}},{"id":1054158,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67624,"kind":"person","name":"Sullivan Eddie Joe","position":1,"cik":"0001889712","reported_name":"Sullivan Eddie Joe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-28T21:00:06.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":3000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share (\"Common Stock\"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the \"Plan\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":3000000,"derivative":{"exercise_price":2.17,"expiration_date":"2035-08-26","underlying":"Common Stock","underlying_shares":3000000},"source":{"system":"sec-edgar","filing":"0000950170-25-112043","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025112043/ownership.xml","form_type":"4"}},{"id":1082477,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-07-24T20:31:07.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":114250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $218.75 per share (the \"Data Release Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Data Release Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Reporting Person in writing of the Phase II Release Date (as defined in the Data Release Warrant)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $218.75 per share (the \"Data Release Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Data Release Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Reporting Person in writing of the Phase II Release Date (as defined in the Data Release Warrant)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $218.75 per share (the \"Data Release Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Data Release Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Reporting Person in writing of the Phase II Release Date (as defined in the Data Release Warrant)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":114250,"derivative":{"exercise_price":218.75,"underlying":"Series B Convertible Preferred Stock","underlying_shares":114250},"source":{"system":"sec-edgar","filing":"0001062993-25-013136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299325013136/form4.xml","form_type":"4"}},{"id":1082476,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-07-24T20:31:07.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":228500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $175 per share (the \"Enrollment Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Enrollment Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Reporting Person in writing of the Phase II Enrollment Date (as defined in the Enrollment Warrant)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $175 per share (the \"Enrollment Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Enrollment Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Reporting Person in writing of the Phase II Enrollment Date (as defined in the Enrollment Warrant)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $175 per share (the \"Enrollment Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Enrollment Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Reporting Person in writing of the Phase II Enrollment Date (as defined in the Enrollment Warrant)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":228500,"derivative":{"exercise_price":175,"underlying":"Series B Convertible Preferred Stock","underlying_shares":228500},"source":{"system":"sec-edgar","filing":"0001062993-25-013136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299325013136/form4.xml","form_type":"4"}},{"id":1082475,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-07-24T20:31:07.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":228500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\") for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025 (the \"SPA\"). The Preferred Stock will automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at a conversion price of $1.75 per share upon the receipt by the Issuer of approval by its stockholders of the issuance of all Common Stock issuable upon conversion of the Series B Preferred Stock at a special meeting of stockholders to be held in accordance with the terms of the SPA (the \"Stockholder Approval\"), subject to the Beneficial Ownership Limitation (as defined below)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\") for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025 (the \"SPA\"). The Preferred Stock will automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at a conversion price of $1.75 per share upon the receipt by the Issuer of approval by its stockholders of the issuance of all Common Stock issuable upon conversion of the Series B Preferred Stock at a special meeting of stockholders to be held in accordance with the terms of the SPA (the \"Stockholder Approval\"), subject to the Beneficial Ownership Limitation (as defined below)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Preferred Stock is subject to a beneficial ownership limitation that prevents the Reporting Persons from converting the Series B Preferred Stock into Common Stock to the extent that such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion (the \"Beneficial Ownership Limitation\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\") for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025 (the \"SPA\"). The Preferred Stock will automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at a conversion price of $1.75 per share upon the receipt by the Issuer of approval by its stockholders of the issuance of all Common Stock issuable upon conversion of the Series B Preferred Stock at a special meeting of stockholders to be held in accordance with the terms of the SPA (the \"Stockholder Approval\"), subject to the Beneficial Ownership Limitation (as defined below)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":228500,"derivative":{"exercise_price":1.75,"underlying":"Common Stock","underlying_shares":22850000},"source":{"system":"sec-edgar","filing":"0001062993-25-013136","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299325013136/form4.xml","form_type":"4"}},{"id":1082474,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-07-24T20:30:04.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":114250,"ownership":{"direct":false,"nature":"See Footnote."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $218.75 per share (the \"Data Release Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Data Release Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Fund in writing of the Phase II Release Date (as defined in the Data Release Warrant)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $218.75 per share (the \"Data Release Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Data Release Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Fund in writing of the Phase II Release Date (as defined in the Data Release Warrant)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $218.75 per share (the \"Data Release Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Data Release Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Fund in writing of the Phase II Release Date (as defined in the Data Release Warrant)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the \"Sessa Parties\"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":114250,"derivative":{"exercise_price":218.75,"underlying":"Series B Convertible Preferred Stock","underlying_shares":114250},"source":{"system":"sec-edgar","filing":"0000950170-25-098365","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025098365/ownership.xml","form_type":"4"}},{"id":1082473,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2025-07-24T20:30:04.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":228500,"ownership":{"direct":false,"nature":"See Footnote."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $175 per share (the \"Enrollment Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Enrollment Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Fund in writing of the Phase II Enrollment Date (as defined in the Enrollment Warrant)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $175 per share (the \"Enrollment Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Enrollment Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Fund in writing of the Phase II Enrollment Date (as defined in the Enrollment Warrant)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $175 per share (the \"Enrollment Warrants\") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Enrollment Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Fund in writing of the Phase II Enrollment Date (as defined in the Enrollment Warrant)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the \"Sessa Parties\"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":228500,"derivative":{"exercise_price":175,"underlying":"Series B Convertible Preferred Stock","underlying_shares":228500},"source":{"system":"sec-edgar","filing":"0000950170-25-098365","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025098365/ownership.xml","form_type":"4"}},{"id":1082472,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-07-24T20:30:04.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":228500,"ownership":{"direct":false,"nature":"See Footnote."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\") for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025 (the \"SPA\"). The Preferred Stock will automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at a conversion price of $1.75 per share upon the receipt by the Issuer of approval by its stockholders of the issuance of all Common Stock issuable upon conversion of the Series B Preferred Stock at a special meeting of stockholders to be held in accordance with the terms of the SPA (the \"Stockholder Approval\"), subject to the Beneficial Ownership Limitation (as defined below)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\") for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025 (the \"SPA\"). The Preferred Stock will automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at a conversion price of $1.75 per share upon the receipt by the Issuer of approval by its stockholders of the issuance of all Common Stock issuable upon conversion of the Series B Preferred Stock at a special meeting of stockholders to be held in accordance with the terms of the SPA (the \"Stockholder Approval\"), subject to the Beneficial Ownership Limitation (as defined below)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Preferred Stock is subject to a beneficial ownership limitation that prevents the Sessa Parties (as defined below) from converting the Series B Preferred Stock into Common Stock to the extent that such conversion would result in the Sessa Parties beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion (the \"Beneficial Ownership Limitation\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the \"Preferred Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\") for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025 (the \"SPA\"). The Preferred Stock will automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at a conversion price of $1.75 per share upon the receipt by the Issuer of approval by its stockholders of the issuance of all Common Stock issuable upon conversion of the Series B Preferred Stock at a special meeting of stockholders to be held in accordance with the terms of the SPA (the \"Stockholder Approval\"), subject to the Beneficial Ownership Limitation (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the \"Sessa Parties\"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":228500,"derivative":{"exercise_price":1.75,"underlying":"Common Stock","underlying_shares":228500},"source":{"system":"sec-edgar","filing":"0000950170-25-098365","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025098365/ownership.xml","form_type":"4"}},{"id":1187278,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-04-01T20:19:49.000Z","date":"2025-03-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":1179,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 24,128 shares of Common Stock and 23,121 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":47249,"source":{"system":"sec-edgar","filing":"0000950170-25-048551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017025048551/ownership.xml","form_type":"4"}},{"id":1320126,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-12-31T22:49:34.000Z","date":"2024-12-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":9072,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's common stock (\"Common Stock\") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 21,712 shares of Common Stock and 26,716 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":48428,"source":{"system":"sec-edgar","filing":"0000950170-24-141672","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024141672/ownership.xml","form_type":"4"}},{"id":1376449,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71236,"kind":"person","name":"Ellias Helen K.","position":1,"cik":"0002001600","reported_name":"Ellias Helen K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-11-05T21:41:10.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on November 1, 2025, 2026, and 2027."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on November 1, 2025, 2026, and 2027."}],"balance_after":35000,"derivative":{"exercise_price":3.88,"expiration_date":"2034-11-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-24-121563","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024121563/ownership.xml","form_type":"4"}},{"id":1376448,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71236,"kind":"person","name":"Ellias Helen K.","position":1,"cik":"0002001600","reported_name":"Ellias Helen K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-11-05T21:41:10.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on November 1, 2025, and 2026."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on November 1, 2025, and 2026."}],"balance_after":20000,"derivative":{"exercise_price":3.88,"expiration_date":"2034-11-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-121563","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024121563/ownership.xml","form_type":"4"}},{"id":1435373,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67621,"kind":"person","name":"To Lucy","position":1,"cik":"0002032049","reported_name":"To Lucy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-08-13T21:00:06.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (August 12, 2025), and the remainder vesting thereafter in equal monthly installments over a three year period."}],"balance_after":125000,"derivative":{"exercise_price":2.35,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000950170-24-096405","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024096405/ownership.xml","form_type":"4"}},{"id":1453212,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":88932,"kind":"person","name":"Spragens Jeffrey G","position":1,"cik":"0001410620","reported_name":"Spragens Jeffrey G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:14.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-084294","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084294/ownership.xml","form_type":"4"}},{"id":1453211,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71237,"kind":"person","name":"Polvino William James","position":1,"cik":"0001889459","reported_name":"Polvino William James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:13.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":13958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027."}],"balance_after":13958,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":13958},"source":{"system":"sec-edgar","filing":"0000950170-24-084293","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084293/ownership.xml","form_type":"4"}},{"id":1453210,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71237,"kind":"person","name":"Polvino William James","position":1,"cik":"0001889459","reported_name":"Polvino William James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:13.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-084293","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084293/ownership.xml","form_type":"4"}},{"id":1453209,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67940,"kind":"person","name":"SKYLER JAY S","position":1,"cik":"0001236386","reported_name":"SKYLER JAY S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:12.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on May 3, 2025, 2026, and 2027."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on May 3, 2025, 2026, and 2027."}],"balance_after":35000,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-24-084299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084299/ownership.xml","form_type":"4"}},{"id":1453208,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67940,"kind":"person","name":"SKYLER JAY S","position":1,"cik":"0001236386","reported_name":"SKYLER JAY S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:12.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-084299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084299/ownership.xml","form_type":"4"}},{"id":1453207,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67624,"kind":"person","name":"Sullivan Eddie Joe","position":1,"cik":"0001889712","reported_name":"Sullivan Eddie Joe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:11.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":4447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028."}],"balance_after":4447,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":4447},"source":{"system":"sec-edgar","filing":"0000950170-24-084292","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084292/ownership.xml","form_type":"4"}},{"id":1453206,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67624,"kind":"person","name":"Sullivan Eddie Joe","position":1,"cik":"0001889712","reported_name":"Sullivan Eddie Joe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:11.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":46528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option are fully vested."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option are fully vested."}],"balance_after":46528,"derivative":{"exercise_price":5.4,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":46528},"source":{"system":"sec-edgar","filing":"0000950170-24-084292","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084292/ownership.xml","form_type":"4"}},{"id":1453205,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":22905,"kind":"person","name":"Lucera Erick","position":1,"cik":"0001697616","reported_name":"Lucera Erick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:09.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-084291","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084291/ownership.xml","form_type":"4"}},{"id":1453204,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":40006,"kind":"person","name":"HAMILTON CHRISTINE E","position":1,"cik":"0001216114","reported_name":"HAMILTON CHRISTINE E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:08.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":2326,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse."},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027."},{"field":"security","element":"securityTitle","label":"F6","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027."}],"balance_after":2326,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":2326},"source":{"system":"sec-edgar","filing":"0000950170-24-084290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084290/ownership.xml","form_type":"4"}},{"id":1453203,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":40006,"kind":"person","name":"HAMILTON CHRISTINE E","position":1,"cik":"0001216114","reported_name":"HAMILTON CHRISTINE E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:08.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":44202,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse."},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option are fully vested."},{"field":"security","element":"securityTitle","label":"F6","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option are fully vested."}],"balance_after":44202,"derivative":{"exercise_price":5.4,"expiration_date":"2024-07-15","underlying":"Common Stock","underlying_shares":44202},"source":{"system":"sec-edgar","filing":"0000950170-24-084290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084290/ownership.xml","form_type":"4"}},{"id":1453202,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":40006,"kind":"person","name":"HAMILTON CHRISTINE E","position":1,"cik":"0001216114","reported_name":"HAMILTON CHRISTINE E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:08.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":4447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027."},{"field":"security","element":"securityTitle","label":"F6","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027."}],"balance_after":4447,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":4447},"source":{"system":"sec-edgar","filing":"0000950170-24-084290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084290/ownership.xml","form_type":"4"}},{"id":1453201,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":40006,"kind":"person","name":"HAMILTON CHRISTINE E","position":1,"cik":"0001216114","reported_name":"HAMILTON CHRISTINE E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:08.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":5815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option are fully vested."},{"field":"security","element":"securityTitle","label":"F6","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option are fully vested."}],"balance_after":5815,"derivative":{"exercise_price":5.4,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":5815},"source":{"system":"sec-edgar","filing":"0000950170-24-084290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084290/ownership.xml","form_type":"4"}},{"id":1453200,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":40006,"kind":"person","name":"HAMILTON CHRISTINE E","position":1,"cik":"0001216114","reported_name":"HAMILTON CHRISTINE E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:08.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."},{"field":"security","element":"securityTitle","label":"F6","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-084290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084290/ownership.xml","form_type":"4"}},{"id":1453199,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":88931,"kind":"person","name":"Link David Charles","position":1,"cik":"0001889464","reported_name":"Link David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:07.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":9305,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027."}],"balance_after":9305,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":9305},"source":{"system":"sec-edgar","filing":"0000950170-24-084296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084296/ownership.xml","form_type":"4"}},{"id":1453198,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":88931,"kind":"person","name":"Link David Charles","position":1,"cik":"0001889464","reported_name":"Link David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:07.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."},{"field":"security","element":"securityTitle","label":"F3","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the \"Board\"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-084296","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084296/ownership.xml","form_type":"4"}},{"id":1453197,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67623,"kind":"person","name":"Reich Samuel J","position":1,"cik":"0001394645","reported_name":"Reich Samuel J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & EXECUTIVE CHAIRMAN"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:05.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":35700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028."}],"balance_after":35700,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":35700},"source":{"system":"sec-edgar","filing":"0000950170-24-084295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084295/ownership.xml","form_type":"4"}},{"id":1453196,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71235,"kind":"person","name":"Giberson Scott","position":1,"cik":"0001937585","reported_name":"Giberson Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:30:03.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."},{"field":"security","element":"securityTitle","label":"F2","text":"This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026."}],"balance_after":20000,"derivative":{"exercise_price":2.9,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-084288","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024084288/ownership.xml","form_type":"4"}},{"id":1623698,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-23T22:00:34.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":140000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000950170-24-019460","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024019460/ownership.xml","form_type":"4"}},{"id":1623697,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67624,"kind":"person","name":"Sullivan Eddie Joe","position":1,"cik":"0001889712","reported_name":"Sullivan Eddie Joe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-23T21:55:10.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":190000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0000950170-24-019441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024019441/ownership.xml","form_type":"4"}},{"id":1623696,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-23T21:50:07.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":140000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0000950170-24-019434","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024019434/ownership.xml","form_type":"4"}},{"id":1623695,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":93963,"kind":"person","name":"King Michael","position":1,"cik":"0001998530","reported_name":"King Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-23T21:45:19.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2014 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":115000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0000950170-24-019432","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024019432/ownership.xml","form_type":"4"}},{"id":1623694,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67623,"kind":"person","name":"Reich Samuel J","position":1,"cik":"0001394645","reported_name":"Reich Samuel J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & EXECUTIVE CHAIRMAN"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-23T21:40:16.000Z","date":"2024-02-21","kind":"grant","planned":false,"acquired":true,"shares":434000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":434000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":434000},"source":{"system":"sec-edgar","filing":"0000950170-24-019430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024019430/ownership.xml","form_type":"4"}},{"id":1718453,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67624,"kind":"person","name":"Sullivan Eddie Joe","position":1,"cik":"0001889712","reported_name":"Sullivan Eddie Joe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-08T13:00:05.000Z","date":"2023-12-07","kind":"purchase","planned":false,"acquired":true,"shares":1740,"price":0.88,"value":1531.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 1,740 shares of the Issuer's common stock, par value $0.0001 per share, acquired by the reporting person in an open market transaction."}],"balance_after":5232304,"source":{"system":"sec-edgar","filing":"0000950170-23-068922","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023068922/ownership.xml","form_type":"4"}},{"id":1727277,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":93963,"kind":"person","name":"King Michael","position":1,"cik":"0001998530","reported_name":"King Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-11-30T22:00:07.000Z","date":"2023-11-30","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":0.9,"value":4500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 5,000 shares of the Issuer's common stock, par value $0.0001 per share, acquired by the reporting person in an open market transaction."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000950170-23-067072","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023067072/ownership.xml","form_type":"4"}},{"id":1727276,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67623,"kind":"person","name":"Reich Samuel J","position":1,"cik":"0001394645","reported_name":"Reich Samuel J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-11-30T13:00:04.000Z","date":"2023-11-29","kind":"purchase","planned":false,"acquired":true,"shares":11000,"price":0.8947,"value":9841.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 11,000 shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), acquired by the reporting person in an open market transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,000 shares of Common Stock held jointly by the reporting person and the reporting person's spouse."}],"balance_after":219001,"source":{"system":"sec-edgar","filing":"0000950170-23-066901","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023066901/ownership.xml","form_type":"4"}},{"id":1729168,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2023-11-28T21:05:50.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":28380,"price":1000,"value":28380000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (\"Common Stock\"), and Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A-2 Preferred Stock is convertible into Common Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, which is filed as Exhibit 3.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 2, 2023. The Series A-2 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-2 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A-2 Preferred Stock is convertible into Common Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, which is filed as Exhibit 3.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 2, 2023. The Series A-2 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-2 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":28380,"derivative":{"exercise_price":0.63,"underlying":"Common Stock","underlying_shares":45047619},"source":{"system":"sec-edgar","filing":"0001062993-23-021502","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323021502/form4.xml","form_type":"4"}},{"id":1729167,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-11-28T21:05:50.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":false,"shares":31269,"price":1000,"value":31269000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (\"Common Stock\"), and Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the automatic conversion of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (\"Common Stock\"), and Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the automatic conversion of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (\"Common Stock\"), and Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.63,"underlying":"Common Stock or Series A-2 Convertible Preferred Stock","underlying_shares":49633333},"source":{"system":"sec-edgar","filing":"0001062993-23-021502","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323021502/form4.xml","form_type":"4"}},{"id":1729166,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T21:05:50.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":4584571,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (\"Common Stock\"), and Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the automatic conversion of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into common stock, par value $0.0001 per share (\"Common Stock\"), and Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":4584571,"source":{"system":"sec-edgar","filing":"0001062993-23-021502","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323021502/form4.xml","form_type":"4"}},{"id":1729171,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2023-11-28T21:05:14.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":28380,"price":1000,"value":28380000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into shares of common stock, par value $0.0001 per share (\"Common Stock\"), and shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A-2 Preferred Stock is convertible into Common Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, which is filed as Exhibit 3.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 2, 2023. The Series A-2 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-2 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A-2 Preferred Stock is convertible into Common Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, which is filed as Exhibit 3.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 2, 2023. The Series A-2 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-2 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":28380,"derivative":{"exercise_price":0.63,"underlying":"Common Stock","underlying_shares":45047619},"source":{"system":"sec-edgar","filing":"0000950170-23-066395","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023066395/ownership.xml","form_type":"4"}},{"id":1729170,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-11-28T21:05:14.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":false,"shares":31269,"price":1000,"value":31269000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into shares of common stock, par value $0.0001 per share (\"Common Stock\"), and shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into shares of common stock, par value $0.0001 per share (\"Common Stock\"), and shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into shares of common stock, par value $0.0001 per share (\"Common Stock\"), and shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.63,"underlying":"Common Stock or Series A-2 Convertible Preferred Stock","underlying_shares":49633333},"source":{"system":"sec-edgar","filing":"0000950170-23-066395","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023066395/ownership.xml","form_type":"4"}},{"id":1729169,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T21:05:14.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":4584571,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into shares of common stock, par value $0.0001 per share (\"Common Stock\"), and shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by Sessa Capital (Master), L.P. (the \"Fund\") into shares of common stock, par value $0.0001 per share (\"Common Stock\"), and shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":4584571,"source":{"system":"sec-edgar","filing":"0000950170-23-066395","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023066395/ownership.xml","form_type":"4"}},{"id":1729165,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71236,"kind":"person","name":"Ellias Helen K.","position":1,"cik":"0002001600","reported_name":"Ellias Helen K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-11-28T21:05:09.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":false,"shares":1800,"price":1000,"value":1800000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by JDRF T1D Fund, LLC (\"JDRF\") into shares of common stock, par value $0.0001 per share (\"Common Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by JDRF T1D Fund, LLC (\"JDRF\") into shares of common stock, par value $0.0001 per share (\"Common Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by JDRF T1D Fund, LLC (\"JDRF\") into shares of common stock, par value $0.0001 per share (\"Common Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are beneficially owned by JDRF, directly. Helen Katherine Ellias, a Managing Director with JDRF, is a member of the board of directors of the Issuer. JDRF is a non-profit organization and the Reporting Person is an employee of such organization. As such, the Reporting Person disclaims beneficial ownership of any securities held by JDRF."}],"balance_after":0,"derivative":{"exercise_price":0.63,"underlying":"Common Stock or Series A-2 Convertible Preferred Stock","underlying_shares":2857142},"source":{"system":"sec-edgar","filing":"0000950170-23-066394","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023066394/ownership.xml","form_type":"4"}},{"id":1729164,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":71236,"kind":"person","name":"Ellias Helen K.","position":1,"cik":"0002001600","reported_name":"Ellias Helen K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T21:05:09.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":2857142,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by JDRF T1D Fund, LLC (\"JDRF\") into shares of common stock, par value $0.0001 per share (\"Common Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), held by JDRF T1D Fund, LLC (\"JDRF\") into shares of common stock, par value $0.0001 per share (\"Common Stock\") of SAB Biotherapeutics, Inc. (the \"Issuer\"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-2 Preferred Stock\"), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are beneficially owned by JDRF, directly. Helen Katherine Ellias, a Managing Director with JDRF, is a member of the board of directors of the Issuer. JDRF is a non-profit organization and the Reporting Person is an employee of such organization. As such, the Reporting Person disclaims beneficial ownership of any securities held by JDRF."}],"balance_after":2857142,"source":{"system":"sec-edgar","filing":"0000950170-23-066394","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023066394/ownership.xml","form_type":"4"}},{"id":1741567,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-11-16T02:10:30.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":13269,"price":1000,"value":13269000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants acquired pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023. The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants acquired pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023. The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Form 4, as originally filed on November 14, 2023, incorrectly reported this number as 13,269. The correct number is 31,269."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":31269,"derivative":{"exercise_price":0.63,"underlying":"Common Stock and/or Series A-2 Preferred Stock","underlying_shares":21061904},"source":{"system":"sec-edgar","filing":"0000950170-23-064323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023064323/ownership.xml","form_type":"4/A","original_submission_date":"2023-11-14"}},{"id":1741566,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-11-15T21:30:55.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":13269,"price":1000,"value":13269000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants acquired pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023. The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants acquired pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023. The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants acquired pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023. The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The Form 4, as originally filed on November 14, 2023, incorrectly reported this number as 21,057,903. The correct number is 21,061,904."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":31269,"derivative":{"exercise_price":0.63,"underlying":"Common Stock or Series A-2 Convertible Preferred Stock","underlying_shares":21061904},"source":{"system":"sec-edgar","filing":"0001062993-23-020902","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323020902/form4a.xml","form_type":"4/A","original_submission_date":"2023-11-14"}},{"id":1743032,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-11-15T00:00:44.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":13269,"price":1000,"value":13269000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the exercise by the Fund of the Tranche A Warrants acquired pursuant to the Transfer Agreement. The shares of Series A-1 Preferred Stock are automatically convertible into shares of the Issuer's common stock, $0.0001 par value per share (\"Common Stock\"), on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer 's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Due to a 1,000 character limit, Footnote 6 is a continuation of Footnote 5: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects the exercise by the Fund of the Tranche A Warrants acquired pursuant to the Transfer Agreement. The shares of Series A-1 Preferred Stock are automatically convertible into shares of the Issuer's common stock, $0.0001 par value per share (\"Common Stock\"), on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer 's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Due to a 1,000 character limit, Footnote 6 is a continuation of Footnote 5: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":13269,"derivative":{"exercise_price":0.63,"underlying":"Common Stock and/or Series A-2 Preferred Stock","underlying_shares":21061904},"source":{"system":"sec-edgar","filing":"0000950170-23-063918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023063918/ownership.xml","form_type":"4"}},{"id":1743031,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Preferred Tranche A Warrants","published_at":"2023-11-15T00:00:44.000Z","date":"2023-11-13","kind":"exercise","planned":false,"acquired":false,"shares":13269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\"), and/or shares of Series A-3 Preferred Stock, par value $0.0001 per share (the \"Series A-3 Preferred Stock\"), pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\"), and/or shares of Series A-3 Preferred Stock, par value $0.0001 per share (the \"Series A-3 Preferred Stock\"), pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\"), and/or shares of Series A-3 Preferred Stock, par value $0.0001 per share (the \"Series A-3 Preferred Stock\"), pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1000,"underlying":"Series A-1 and/or A-3 Convertible Preferred Stock","underlying_shares":13269},"source":{"system":"sec-edgar","filing":"0000950170-23-063918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023063918/ownership.xml","form_type":"4"}},{"id":1743030,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Preferred Tranche C Warrants","published_at":"2023-11-15T00:00:44.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":22115,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the acquisition by the Fund of Tranche C Warrants (the \"Tranche C Warrants\") to purchase shares of Series A-3 Preferred Stock, pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche C Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche C Warrant) until the five (5) year anniversary of such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the acquisition by the Fund of Tranche C Warrants (the \"Tranche C Warrants\") to purchase shares of Series A-3 Preferred Stock, pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche C Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche C Warrant) until the five (5) year anniversary of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Reflects the acquisition by the Fund of Tranche C Warrants (the \"Tranche C Warrants\") to purchase shares of Series A-3 Preferred Stock, pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche C Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche C Warrant) until the five (5) year anniversary of such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":52115,"derivative":{"exercise_price":1000,"underlying":"Series A-3 Preferred Stock","underlying_shares":22115},"source":{"system":"sec-edgar","filing":"0000950170-23-063918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023063918/ownership.xml","form_type":"4"}},{"id":1743029,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Preferred Tranche B Warrants","published_at":"2023-11-15T00:00:44.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":8846,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the acquisition by the Fund of Tranche B Warrants (the \"Tranche B Warrants\") to purchase shares of Series A-3 Preferred Stock, pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche B Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche B Warrant) until the later of (i) 21 days following the Issuer 's announcement of data from its SAB-142-101 clinical trial and (ii) March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects the acquisition by the Fund of Tranche B Warrants (the \"Tranche B Warrants\") to purchase shares of Series A-3 Preferred Stock, pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche B Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche B Warrant) until the later of (i) 21 days following the Issuer 's announcement of data from its SAB-142-101 clinical trial and (ii) March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Reflects the acquisition by the Fund of Tranche B Warrants (the \"Tranche B Warrants\") to purchase shares of Series A-3 Preferred Stock, pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche B Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche B Warrant) until the later of (i) 21 days following the Issuer 's announcement of data from its SAB-142-101 clinical trial and (ii) March 31, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":20846,"derivative":{"exercise_price":1000,"underlying":"Series A-3 Preferred Stock","underlying_shares":8846},"source":{"system":"sec-edgar","filing":"0000950170-23-063918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023063918/ownership.xml","form_type":"4"}},{"id":1743028,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Preferred Tranche A Warrants","published_at":"2023-11-15T00:00:44.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":13269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\"), and/or shares of Series A-3 Preferred Stock, par value $0.0001 per share (the \"Series A-3 Preferred Stock\"), pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\"), and/or shares of Series A-3 Preferred Stock, par value $0.0001 per share (the \"Series A-3 Preferred Stock\"), pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the \"Series A-1 Preferred Stock\"), and/or shares of Series A-3 Preferred Stock, par value $0.0001 per share (the \"Series A-3 Preferred Stock\"), pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":13269,"derivative":{"exercise_price":1000,"underlying":"Series A-1 and/or A-3 Convertible Preferred Stock","underlying_shares":13269},"source":{"system":"sec-edgar","filing":"0000950170-23-063918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023063918/ownership.xml","form_type":"4"}},{"id":1743027,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-11-14T21:08:14.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":13269,"price":1000,"value":13269000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the exercise by the Fund of the Tranche A Warrants acquired pursuant to the Transfer Agreement. The shares of Series A-1 Preferred Stock are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of the Issuer on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Due to a 1,000 character limit, Footnote 6 is a continuation of Footnote 5: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the exercise by the Fund of the Tranche A Warrants acquired pursuant to the Transfer Agreement. The shares of Series A-1 Preferred Stock are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of the Issuer on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Due to a 1,000 character limit, Footnote 6 is a continuation of Footnote 5: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects the exercise by the Fund of the Tranche A Warrants acquired pursuant to the Transfer Agreement. The shares of Series A-1 Preferred Stock are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of the Issuer on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Due to a 1,000 character limit, Footnote 6 is a continuation of Footnote 5: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":31269,"derivative":{"exercise_price":0.63,"underlying":"Common Stock or Series A-2 Convertible Preferred Stock","underlying_shares":21057903},"source":{"system":"sec-edgar","filing":"0001062993-23-020791","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323020791/form4.xml","form_type":"4"}},{"id":1743026,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche A Warrants","published_at":"2023-11-14T21:08:14.000Z","date":"2023-11-13","kind":"exercise","planned":false,"acquired":false,"shares":13269,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the exercise by the Fund of the Tranche A Warrants acquired pursuant to the Transfer Agreement. The shares of Series A-1 Preferred Stock are automatically convertible into shares of common stock, $0.0001 par value per share (\"Common Stock\"), of the Issuer on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Due to a 1,000 character limit, Footnote 6 is a continuation of Footnote 5: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of SAB Biotherapeutics, Inc. (the \"Issuer\") pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of SAB Biotherapeutics, Inc. (the \"Issuer\") pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of SAB Biotherapeutics, Inc. (the \"Issuer\") pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1000,"underlying":"Series A-1 or Series A-3 Convertible Preferred Stock","underlying_shares":13269},"source":{"system":"sec-edgar","filing":"0001062993-23-020791","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323020791/form4.xml","form_type":"4"}},{"id":1743025,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche C Warrants","published_at":"2023-11-14T21:08:14.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":22115,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the acquisition by the Fund of Tranche C Warrants (the \"Tranche C Warrants\") to purchase shares of Series A-3 Preferred Stock of the Issuer pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche C Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche C Warrant) until the five (5) year anniversary of such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the acquisition by the Fund of Tranche C Warrants (the \"Tranche C Warrants\") to purchase shares of Series A-3 Preferred Stock of the Issuer pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche C Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche C Warrant) until the five (5) year anniversary of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Reflects the acquisition by the Fund of Tranche C Warrants (the \"Tranche C Warrants\") to purchase shares of Series A-3 Preferred Stock of the Issuer pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche C Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche C Warrant) until the five (5) year anniversary of such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":52115,"derivative":{"exercise_price":1000,"underlying":"Series A-3 Convertible Preferred Stock","underlying_shares":22115},"source":{"system":"sec-edgar","filing":"0001062993-23-020791","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323020791/form4.xml","form_type":"4"}},{"id":1743024,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche B Warrants","published_at":"2023-11-14T21:08:14.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":8846,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the acquisition by the Fund of Tranche B Warrants (the \"Tranche B Warrants\") to purchase shares of Series A-3 Preferred Stock of the Issuer pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche B Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche B Warrant) until the later of (i) 21 days following the Issuer's announcement of data from its SAB-142-101 clinical trial and (ii) March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects the acquisition by the Fund of Tranche B Warrants (the \"Tranche B Warrants\") to purchase shares of Series A-3 Preferred Stock of the Issuer pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche B Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche B Warrant) until the later of (i) 21 days following the Issuer's announcement of data from its SAB-142-101 clinical trial and (ii) March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Reflects the acquisition by the Fund of Tranche B Warrants (the \"Tranche B Warrants\") to purchase shares of Series A-3 Preferred Stock of the Issuer pursuant to the Transfer Agreement in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche B Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche B Warrant) until the later of (i) 21 days following the Issuer's announcement of data from its SAB-142-101 clinical trial and (ii) March 31, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":20846,"derivative":{"exercise_price":1000,"underlying":"Series A-3 Convertible Preferred Stock","underlying_shares":8846},"source":{"system":"sec-edgar","filing":"0001062993-23-020791","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323020791/form4.xml","form_type":"4"}},{"id":1743023,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche A Warrants","published_at":"2023-11-14T21:08:14.000Z","date":"2023-11-10","kind":"grant","planned":false,"acquired":true,"shares":13269,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of SAB Biotherapeutics, Inc. (the \"Issuer\") pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of SAB Biotherapeutics, Inc. (the \"Issuer\") pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the acquisition by Sessa Capital (Master), L.P. (the \"Fund\") of Tranche A Warrants (the \"Tranche A Warrants\") to purchase shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\"), or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of SAB Biotherapeutics, Inc. (the \"Issuer\") pursuant to a Warrant Amendment and Transfer Agreement, dated as of November 10, 2023 (the \"Transfer Agreement\"), in consideration for an agreement to exercise the Tranche A Warrants on or before November 14, 2023. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until November 14, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":13269,"derivative":{"exercise_price":1000,"underlying":"Series A-1 or Series A-3 Convertible Preferred Stock","underlying_shares":13269},"source":{"system":"sec-edgar","filing":"0001062993-23-020791","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323020791/form4.xml","form_type":"4"}},{"id":1750708,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":93963,"kind":"person","name":"King Michael","position":1,"cik":"0001998530","reported_name":"King Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-11-03T20:50:05.000Z","date":"2023-10-30","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents options to purchase shares of common stock of the Registrant pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan. The exercise price of the options was determined as of the date that the compensation committee of the board of directors of the Registrant approved the award, October 19, 2023. The award was contingent upon the Reporting Person's commencement of service as Chief Financial Officer of the Registrant, which occurred on October 30, 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock of the Registrant pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan. The exercise price of the options was determined as of the date that the compensation committee of the board of directors of the Registrant approved the award, October 19, 2023. The award was contingent upon the Reporting Person's commencement of service as Chief Financial Officer of the Registrant, which occurred on October 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (October 30, 2024), and the remainder vesting thereafter in equal monthly installments over a three year period."}],"balance_after":850000,"derivative":{"exercise_price":0.798,"expiration_date":"2033-10-30","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0000950170-23-058894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023058894/ownership.xml","form_type":"4"}},{"id":1755985,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche A Warrants","published_at":"2023-10-24T21:33:30.000Z","date":"2023-10-23","kind":"exercise","planned":false,"acquired":false,"shares":16269,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the SPA, the Fund acquired Tranche A Warrants to purchase shares of Series A-1 Preferred Stock or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the \"Tranche A Warrants\"), on the terms summarized in the Issuer's Current Report on Form 8-K filed on October 2, 2023, including the exhibits thereto. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until the earlier of (i) fifteen (15) trading days following the date of public announcement of the fulsome data set from the Sanofi S.A. Protect trial and (ii) December 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the SPA, the Fund acquired Tranche A Warrants to purchase shares of Series A-1 Preferred Stock or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the \"Tranche A Warrants\"), on the terms summarized in the Issuer's Current Report on Form 8-K filed on October 2, 2023, including the exhibits thereto. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until the earlier of (i) fifteen (15) trading days following the date of public announcement of the fulsome data set from the Sanofi S.A. Protect trial and (ii) December 15, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the SPA, the Fund acquired Tranche A Warrants to purchase shares of Series A-1 Preferred Stock or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the \"Tranche A Warrants\"), on the terms summarized in the Issuer's Current Report on Form 8-K filed on October 2, 2023, including the exhibits thereto. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until the earlier of (i) fifteen (15) trading days following the date of public announcement of the fulsome data set from the Sanofi S.A. Protect trial and (ii) December 15, 2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1000,"underlying":"Series A-1 or Series A-3 Convertible Preferred Stock","underlying_shares":16269},"source":{"system":"sec-edgar","filing":"0001062993-23-019668","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323019668/form4.xml","form_type":"4"}},{"id":1755984,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74790,"kind":"person","name":"Sessa Capital (Master), L.P.","position":1,"cik":"0001618360","reported_name":"Sessa Capital (Master), L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74791,"kind":"person","name":"Sessa Capital GP, LLC","position":2,"cik":"0001618699","reported_name":"Sessa Capital GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74792,"kind":"person","name":"Sessa Capital IM, L.P.","position":3,"cik":"0001595849","reported_name":"Sessa Capital IM, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74793,"kind":"person","name":"Sessa Capital IM GP, LLC","position":4,"cik":"0001618700","reported_name":"Sessa Capital IM GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74794,"kind":"person","name":"Petry John","position":5,"cik":"0001618702","reported_name":"Petry John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-10-24T21:33:30.000Z","date":"2023-10-23","kind":"grant","planned":false,"acquired":true,"shares":16269,"price":1000,"value":16269000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of the Tranche A Warrants (as defined below) acquired pursuant to a Securities Purchase Agreement, dated as of September 29, 2023 (the \"SPA\"). The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\") are automatically convertible into shares of Common Stock of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of common stock, $0.0001 par value per share (\"Common Stock\"), of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of the Tranche A Warrants (as defined below) acquired pursuant to a Securities Purchase Agreement, dated as of September 29, 2023 (the \"SPA\"). The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\") are automatically convertible into shares of Common Stock of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of common stock, $0.0001 par value per share (\"Common Stock\"), of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Persons from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Persons beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Persons' beneficial ownership to exceed such maximum percentage, the Reporting Persons will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Each of the Reporting Persons and Mr. Petry disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":18000,"derivative":{"exercise_price":0.63,"underlying":"Common Stock or Series A-2 Convertible Preferred Stock","underlying_shares":25818903},"source":{"system":"sec-edgar","filing":"0001062993-23-019668","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000106299323019668/form4.xml","form_type":"4"}},{"id":1755983,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Preferred Tranche A Warrants","published_at":"2023-10-24T21:30:08.000Z","date":"2023-10-23","kind":"exercise","planned":false,"acquired":false,"shares":16269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the SPA, the Fund acquired Tranche A Warrants to purchase shares of Series A-1 Preferred Stock or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the \"Tranche A Warrants\"), on the terms summarized in the Issuer's Current Report on Form 8-K filed on October 2, 2023, including the exhibits thereto. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until the earlier of (i) fifteen (15) trading days following the date of public announcement of the fulsome data set from the Sanofi S.A. Protect trial and (ii) December 15, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the SPA, the Fund acquired Tranche A Warrants to purchase shares of Series A-1 Preferred Stock or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the \"Tranche A Warrants\"), on the terms summarized in the Issuer's Current Report on Form 8-K filed on October 2, 2023, including the exhibits thereto. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until the earlier of (i) fifteen (15) trading days following the date of public announcement of the fulsome data set from the Sanofi S.A. Protect trial and (ii) December 15, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the SPA, the Fund acquired Tranche A Warrants to purchase shares of Series A-1 Preferred Stock or shares of Series A-3 Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the \"Tranche A Warrants\"), on the terms summarized in the Issuer's Current Report on Form 8-K filed on October 2, 2023, including the exhibits thereto. The Tranche A Warrants became exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until the earlier of (i) fifteen (15) trading days following the date of public announcement of the fulsome data set from the Sanofi S.A. Protect trial and (ii) December 15, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Registrant. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1000,"underlying":"Series A-1 and/or A-3 Convertible Preferred Stock","underlying_shares":16269},"source":{"system":"sec-edgar","filing":"0000950170-23-054936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023054936/ownership.xml","form_type":"4"}},{"id":1755982,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":74795,"kind":"person","name":"Moin Andrew","position":1,"cik":"0001996040","reported_name":"Moin Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2023-10-24T21:30:08.000Z","date":"2023-10-23","kind":"grant","planned":false,"acquired":true,"shares":16269,"price":1000,"value":16269000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of the Tranche A Warrants (as defined below) acquired pursuant to a Securities Purchase Agreement, dated as of September 29, 2023 (the \"SPA\"). The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\") are automatically convertible into shares of Common Stock of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of common stock, $0.0001 par value per share (\"Common Stock\"), of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the exercise by Sessa Capital (Master), L.P. (the \"Fund\") of the Tranche A Warrants (as defined below) acquired pursuant to a Securities Purchase Agreement, dated as of September 29, 2023 (the \"SPA\"). The shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share (\"Series A-1 Preferred Stock\") are automatically convertible into shares of Common Stock of SAB Biotherapeutics, Inc. (the \"Issuer\") on the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Certificate of Incorporation to increase the number of authorized shares of common stock, $0.0001 par value per share (\"Common Stock\"), of the Issuer and (ii) the issuance of the Series A-1 Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Convertible Preferred Stock, par value $0.0001 per share, in lieu of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with Sessa Capital, is a member of the board of directors of the Registrant. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein."}],"balance_after":18000,"derivative":{"exercise_price":0.63,"underlying":"Common Stock and/or Series A-2 Preferred Stock","underlying_shares":25818903},"source":{"system":"sec-edgar","filing":"0000950170-23-054936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017023054936/ownership.xml","form_type":"4"}},{"id":1926053,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":22905,"kind":"person","name":"Lucera Erick","position":1,"cik":"0001697616","reported_name":"Lucera Erick","relationship":{"director":true}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-04-05T21:01:45.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a three-year period, vesting 1/36 monthly beginning with the month following the Reporting Person's commencement of service as a director (April 3, 2023). This represents the initial grant to the Reporting Person as a member of the Board of Directors."}],"balance_after":25000,"derivative":{"exercise_price":0.465,"expiration_date":"2033-04-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-23-009554","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923009554/rdgdoc.xml","form_type":"4"}},{"id":1951149,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":35282,"kind":"person","name":"Kropotova Alexandra","position":1,"cik":"0001825323","reported_name":"Kropotova Alexandra","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-16T20:30:22.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":275000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Unit (\"RSU\") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on March 14, 2024, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Unit (\"RSU\") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on March 14, 2024, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":275000,"source":{"system":"sec-edgar","filing":"0001437749-23-006913","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923006913/rdgdoc.xml","form_type":"4"}},{"id":1951148,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67624,"kind":"person","name":"Sullivan Eddie Joe","position":1,"cik":"0001889712","reported_name":"Sullivan Eddie Joe","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-16T20:29:27.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":525000,"derivative":{"exercise_price":0.54,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0001437749-23-006911","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923006911/rdgdoc.xml","form_type":"4"}},{"id":1951147,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67623,"kind":"person","name":"Reich Samuel J","position":1,"cik":"0001394645","reported_name":"Reich Samuel J","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-16T20:28:42.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":525000,"derivative":{"exercise_price":0.54,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0001437749-23-006910","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923006910/rdgdoc.xml","form_type":"4"}},{"id":1951146,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67622,"kind":"person","name":"Bausch Christoph Lawrence","position":1,"cik":"0001889981","reported_name":"Bausch Christoph Lawrence","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-16T20:28:08.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":275000,"derivative":{"exercise_price":0.54,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001437749-23-006909","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923006909/rdgdoc.xml","form_type":"4"}},{"id":1951145,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-16T20:27:20.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":275000,"derivative":{"exercise_price":0.54,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001437749-23-006908","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923006908/rdgdoc.xml","form_type":"4"}},{"id":1981708,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":88932,"kind":"person","name":"Spragens Jeffrey G","position":1,"cik":"0001410620","reported_name":"Spragens Jeffrey G","relationship":{"director":true}}],"security":"Warrants","published_at":"2023-03-02T14:20:24.000Z","date":"2023-02-28","kind":"other","acquired":true,"shares":19936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a member of Big Cypress Holdings LLC, and as part of the distribution received 19,936 warrants of the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a member of Big Cypress Holdings LLC, and as part of the distribution received 19,936 warrants of the issuer."}],"balance_after":19936,"derivative":{"exercise_price":11.5,"exercise_date":"2022-01-14","expiration_date":"2026-10-20","underlying":"Common Stock","underlying_shares":19936},"source":{"system":"sec-edgar","filing":"0001437749-23-005167","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923005167/rdgdoc.xml","form_type":"4"}},{"id":1981707,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67623,"kind":"person","name":"Reich Samuel J","position":1,"cik":"0001394645","reported_name":"Reich Samuel J","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Warrants","published_at":"2023-03-02T14:18:12.000Z","date":"2023-02-28","kind":"other","acquired":true,"shares":9968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person received 9,968 warrants as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person received 9,968 warrants as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis."}],"balance_after":9968,"derivative":{"exercise_price":11.5,"exercise_date":"2022-01-14","expiration_date":"2026-10-20","underlying":"Common Stock","underlying_shares":9968},"source":{"system":"sec-edgar","filing":"0001437749-23-005165","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923005165/rdgdoc.xml","form_type":"4"}},{"id":1981706,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":67623,"kind":"person","name":"Reich Samuel J","position":1,"cik":"0001394645","reported_name":"Reich Samuel J","relationship":{"director":true,"officer":true,"officer_title":"Executive Chairman"}}],"security":"Warrants","published_at":"2023-03-02T14:18:12.000Z","date":"2023-02-28","kind":"other","acquired":false,"shares":208600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Big Cypress Holdings LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution received 9,968 warrants of the issuer, which the Reporting Person previously had an indirect pecuniary interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution received 9,968 warrants of the issuer, which the Reporting Person previously had an indirect pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2022-01-14","expiration_date":"2026-10-20","underlying":"Common Stock","underlying_shares":208600},"source":{"system":"sec-edgar","filing":"0001437749-23-005165","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923005165/rdgdoc.xml","form_type":"4"}},{"id":2023768,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":40006,"kind":"person","name":"HAMILTON CHRISTINE E","position":1,"cik":"0001216114","reported_name":"HAMILTON CHRISTINE E","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-02-10T21:14:04.000Z","date":"2022-06-07","kind":"gift","acquired":false,"shares":2000000,"ownership":{"direct":false,"nature":"By spouse."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a bona fide gift of common stock for no consideration."}],"balance_after":3083270,"source":{"system":"sec-edgar","filing":"0001437749-23-003040","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923003040/rdgdoc.xml","form_type":"5"}},{"id":2091617,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":40006,"kind":"person","name":"HAMILTON CHRISTINE E","position":1,"cik":"0001216114","reported_name":"HAMILTON CHRISTINE E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Common Stock)","published_at":"2022-12-09T21:31:28.000Z","date":"2022-12-07","kind":"grant","acquired":true,"shares":82987,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 6, 2022, the Registrant entered into a securities purchase agreement with Ms. Christine Hamilton and Dr. Edward Hamilton in connection with a private placement conducted by the Registrant, pursuant to which Ms. Hamilton and Dr. Hamilton purchased (i) an aggregate of 82,987 shares (the \"Shares\") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance."}],"balance_after":82987,"derivative":{"exercise_price":1.08,"exercise_date":"2023-06-07","expiration_date":"2027-12-07","underlying":"Common Stock","underlying_shares":82987},"source":{"system":"sec-edgar","filing":"0001209191-22-060501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000120919122060501/doc4.xml","form_type":"4"}},{"id":2091616,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":40006,"kind":"person","name":"HAMILTON CHRISTINE E","position":1,"cik":"0001216114","reported_name":"HAMILTON CHRISTINE E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-09T21:31:28.000Z","date":"2022-12-07","kind":"grant","acquired":true,"shares":82987,"price":1.205,"value":99999.335,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On December 6, 2022, the Registrant entered into a securities purchase agreement with Ms. Christine Hamilton and Dr. Edward Hamilton in connection with a private placement conducted by the Registrant, pursuant to which Ms. Hamilton and Dr. Hamilton purchased (i) an aggregate of 82,987 shares (the \"Shares\") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 6, 2022, the Registrant entered into a securities purchase agreement with Ms. Christine Hamilton and Dr. Edward Hamilton in connection with a private placement conducted by the Registrant, pursuant to which Ms. Hamilton and Dr. Hamilton purchased (i) an aggregate of 82,987 shares (the \"Shares\") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects dispositions of 2,000,000 shares of common stock by Ms. Hamilton's spouse for bona fide estate planning purposes exempt from the report requirements of Section 16 under the Securities Exchange Act of 1934, as amended."}],"balance_after":3111334,"source":{"system":"sec-edgar","filing":"0001209191-22-060501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000120919122060501/doc4.xml","form_type":"4"}}],"next_cursor":"2022-12-09T21:31:28.000000Z,2091616"}